GLP-1 vs GLP-2: The Difference, and What 'GLP-1 Inhibitors' Really Means

GLP-1 vs GLP-2 comes down to one precursor protein and two very different jobs: GLP-1 (glucagon-like peptide-1) controls appetite, insulin, and satiety, which is why it became the basis for Ozempic, Wegovy, and Zepbound, while GLP-2 (glucagon-like peptide-2) grows and repairs the lining of the intestine, which is why its only approved drug, teduglutide, treats short bowel syndrome rather than obesity. Both hormones are released by the same gut cells after a meal, and both are cut from the same parent molecule, but they act on separate receptors and produce almost unrelated effects. If you arrived here searching for "GLP-1 inhibitors," there is a second thing worth clearing up right away: the weight and diabetes drugs everyone is talking about are not inhibitors at all. They are agonists. They activate the GLP-1 receptor rather than block it.

This guide explains the GLP-1 vs GLP-2 distinction in plain terms, gives you a side-by-side comparison table, and untangles the "inhibitor" confusion so you know exactly what these medications are and what they do.

GLP-1 vs GLP-2: same origin, different jobs

GLP-1 and GLP-2 are both peptide hormones, meaning short chains of amino acids. They are cut from a single larger precursor protein called proglucagon, the same precursor that also yields glucagon. When the body processes proglucagon in the gut, it snips out several fragments, and two of those fragments are GLP-1 and GLP-2. They sit next to each other on the same parent molecule and are released together, in roughly equal amounts, by the same cells.

Those cells are the L-cells in the lining of the lower small intestine and colon. When food arrives, the L-cells secrete GLP-1 and GLP-2 into the bloodstream at the same time. So far the two hormones look like twins: same source, same trigger, same release. The divergence happens at the receptor. GLP-1 binds the GLP-1 receptor, which is found in the pancreas, stomach, and brain. GLP-2 binds the GLP-2 receptor, which sits almost entirely in the gut itself. Different receptors in different tissues produce different outcomes, and that is the whole story of GLP-1 vs GLP-2. The background on where GLP-1 comes from and how the body makes it is covered in natural GLP-1 in the body.

What GLP-1 does

GLP-1 is the hormone behind the modern weight-loss and diabetes drugs, and it earns that role through four main actions. It stimulates insulin release from the pancreas, but only when blood sugar is high, which is why GLP-1 based drugs rarely cause dangerously low blood sugar on their own. It suppresses glucagon, the hormone that raises blood sugar. It slows the rate at which the stomach empties, so a meal produces a longer sense of fullness. And it acts on the brain to increase satiety and quiet the persistent pull toward food that many people call food noise.

Put together, those effects reduce appetite and food intake while improving blood-sugar control. That combination is what makes GLP-1 such a useful drug target, and it is why a hormone first studied for diabetes turned into the most effective weight-management medication class yet developed. A fuller account of the biology sits in what GLP-1 is and, for the weight-loss mechanism specifically, in how semaglutide works for weight loss. GLP-1 is also one of the two main incretins, and it is often compared with its partner hormone GIP, a comparison laid out in the difference between GLP-1 and GIP.

What GLP-2 does

GLP-2 works entirely in the gut, and its job is structural rather than metabolic. It promotes the growth of the intestinal lining, increasing the height of the villi and the depth of the crypts, which expands the surface area available for absorbing nutrients. It enhances mucosal blood flow, strengthens the gut barrier, and slows gut transit modestly. In short, GLP-2 helps the intestine grow, repair, and absorb more efficiently. It has no meaningful effect on appetite, insulin, or weight.

That gut-growth action is exactly why GLP-2 became a treatment for short bowel syndrome, a condition in which people have lost a large portion of their small intestine to surgery or disease and cannot absorb enough nutrients and fluid. A GLP-2 analog, teduglutide (sold as Gattex in the United States and Revestive elsewhere), is given to these patients to coax the remaining intestine into absorbing more, reducing their dependence on intravenous nutrition. It is a specialist drug for a rare condition, prescribed by gastroenterologists, and it has nothing to do with weight loss. This is the single most important practical point in the GLP-1 vs GLP-2 comparison: the two hormones power two completely different categories of medicine.

GLP-1 vs GLP-2: the comparison table

Here is the side-by-side view of GLP-1 vs GLP-2, from origin to clinical use.

Feature	GLP-1 (glucagon-like peptide-1)	GLP-2 (glucagon-like peptide-2)
Precursor	Proglucagon	Proglucagon (same precursor)
Released by	Intestinal L-cells after eating	Intestinal L-cells after eating
Length	About 30 to 31 amino acids	About 33 amino acids
Receptor location	Pancreas, stomach, brain	Mostly the gut itself
Main effects	Glucose-dependent insulin release, glucagon suppression, slowed gastric emptying, increased satiety	Intestinal growth, better nutrient absorption, gut barrier integrity, mucosal blood flow
Effect on appetite or weight	Strong: reduces appetite and food intake	None meaningful
Approved drugs	Semaglutide, tirzepatide, liraglutide, dulaglutide, exenatide (GLP-1 receptor agonists)	Teduglutide (a GLP-2 receptor agonist)
Main use	Type 2 diabetes and weight management	Short bowel syndrome

Read down the table and the pattern is clear. The two hormones share an origin and a release mechanism, then split completely at the receptor. Everything that matters clinically, from the target organ to the disease treated, follows from that split.

"GLP-1 inhibitors" is almost always the wrong name

One of the most common searches in this space is "GLP-1 inhibitors" or "list of GLP-1 inhibitors," and it is built on a misunderstanding worth correcting carefully. The weight-loss and diabetes drugs, including Ozempic, Wegovy, Mounjaro, and Zepbound, are not inhibitors. They are agonists. An agonist activates a receptor; an inhibitor or antagonist blocks it. These drugs switch the GLP-1 receptor on, mimicking the natural hormone, so the body behaves as if it has a long-lasting supply of GLP-1. They turn the system up, not down.

The correct name is GLP-1 receptor agonist, often shortened to GLP-1 RA. So when someone asks for a "list of GLP-1 inhibitors" for weight loss, what they almost always want is a list of GLP-1 receptor agonists. The full drug class is described in the GLP-1 receptor agonists drug class.

Where does the word "inhibitor" come from, then? Probably from two real but different drug names. The first is the DPP-4 inhibitors, a separate class of diabetes pills such as sitagliptin (Januvia) and linagliptin (Tradjenta). DPP-4 is the enzyme that rapidly breaks down natural GLP-1. By inhibiting that enzyme, DPP-4 inhibitors let your own GLP-1 last a little longer. They work through the GLP-1 system, but indirectly, and they are far weaker than the injectable agonists. The second source of confusion is SGLT2 inhibitors (such as empagliflozin and dapagliflozin), another diabetes class that is frequently mentioned alongside GLP-1 drugs but works on the kidney and has nothing to do with GLP-1 at all. So "inhibitor" is a real word in diabetes medicine, just attached to the wrong class when applied to Ozempic-style drugs.

Quick reference: agonist vs inhibitor

• GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide): activate the GLP-1 receptor. These are the weight and diabetes drugs.
• DPP-4 inhibitors (sitagliptin, linagliptin): block the enzyme that destroys your own GLP-1. Indirect, milder, oral.
• SGLT2 inhibitors (empagliflozin, dapagliflozin): act on the kidney; unrelated to GLP-1.

The drugs people mean when they search "GLP-1 inhibitors"

If you came looking for a list, here are the actual GLP-1 receptor agonists approved in the United States, by active ingredient:

• Semaglutide: Ozempic and Rybelsus (type 2 diabetes), Wegovy (weight management). The oral Rybelsus tablet is the same molecule in pill form.
• Tirzepatide: Mounjaro (diabetes) and Zepbound (weight management). Strictly, tirzepatide is a dual GLP-1 and GIP receptor agonist, so it activates two receptors at once.
• Liraglutide: Victoza (diabetes) and Saxenda (weight management). An older, daily-injection agent.
• Dulaglutide: Trulicity (diabetes).
• Exenatide: Byetta and Bydureon (diabetes), the first of the class to reach market.

Every drug on that list is an agonist, not an inhibitor. None of them is GLP-2, and none of them is used for the gut conditions GLP-2 treats. The single GLP-2 agonist in clinical use, teduglutide, would never appear on a weight-loss list, which is the practical payoff of understanding GLP-1 vs GLP-2 in the first place.

Is there a GLP-3? And where does GLP-2 fit in weight loss?

A related search asks about "GLP-3." There is no established hormone called GLP-3 in human physiology, and no GLP-3 drug. The proglucagon precursor yields glucagon, GLP-1, and GLP-2, and that is where the numbered series ends. Marketing copy that references "GLP-3" is generally not describing a recognized hormone, so treat it with caution.

As for GLP-2 and weight, the honest answer is that GLP-2 is not a weight-loss hormone and is not being developed as one. Its gut-growth action is the opposite of what a weight drug needs. The genuine frontier in this field is combining GLP-1 with other metabolic hormones, such as GIP (already done in tirzepatide) and glucagon, not adding GLP-2. So if a clinic advertises GLP-2 for weight loss, that is a reason to ask questions, because the established science does not support it.

What this means if you are considering a GLP-1 medication

For almost everyone researching GLP-1 vs GLP-2 in the context of weight loss or diabetes, GLP-1 is the relevant hormone and a GLP-1 receptor agonist is the relevant medicine. These are prescription drugs, evaluated by a clinician against your weight, health history, and goals, and they require a proper assessment rather than a casual purchase. The clinical evidence behind them is unusually strong: in large randomized trials, semaglutide produced about 14.9% mean weight loss over 68 weeks and high-dose tirzepatide up to about 20.9% over 72 weeks.

Getting started has become more straightforward than it used to be. Licensed online telehealth services now connect patients with clinicians who can assess eligibility, prescribe an appropriate GLP-1 receptor agonist when suitable, and arrange ongoing follow-up, all without a misnomer like "inhibitor" getting in the way. If you have established that a GLP-1, and not GLP-2, is what fits your situation, a reputable telehealth provider is often the simplest route to a proper evaluation and, where appropriate, a prescription with medical oversight.

Key takeaways

• GLP-1 and GLP-2 come from the same precursor (proglucagon) and the same gut cells, but act on different receptors and do different jobs.
• GLP-1 controls appetite, insulin, and satiety, which is why it underpins Ozempic, Wegovy, Mounjaro, and Zepbound.
• GLP-2 grows and repairs the intestine; its only approved drug, teduglutide (Gattex), treats short bowel syndrome, not obesity.
• "GLP-1 inhibitors" is a misnomer. The weight and diabetes drugs are GLP-1 receptor agonists: they activate the receptor, not block it.
• The word "inhibitor" properly belongs to separate diabetes classes, the DPP-4 inhibitors and SGLT2 inhibitors.
• There is no recognized GLP-3 hormone, and GLP-2 is not a weight-loss treatment.

For the full picture of how these medications work, what the trials show, and how to access them, see the complete guide to GLP-1 medications and weight science.